Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Jun 11;204(6):1441–1451. doi: 10.1084/jem.20070021

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 7. — Tumoricidal activity of blood-derived mDCs and pDCs after stimulation with TLR7/8 agonists. Unstimulated, TLR7/8- stimulated, or vehicle-stimulated (A) mDCs and (B) pDCs were cultured with K562 or Jurkat as target cells for a conventional 2-h europium-TDA release assay at the indicated effector/target cell ratios. Data represent the means of triplicate wells ± SEM from two independent experiments. (C and D) For inhibition of different cytotoxicity-inducing pathways, 12-h TLR7/8-stimulated mDCs and pDCs as effector cells were preincubated with 100 nM concanamycin A for 120 min, 5 μg/ml anti-TRAIL for 30 min, 5 μg/ml anti-Fas ligand for 30 min, or 5 μg/ml of an IgG1 isotype for 30 min. Target cells were (C) K562 for TLR7/8-stimulated mDCs and (D) Jurkat for TLR7/8-stimulated pDCs. Cytotoxicity was determined by a 2-h europium-TDA release assay at the indicated effector/target cell ratios. Data represent the means of triplicate wells ± SEM from two independent experiments.